EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSSTOG00000008575
Gene Symbol: GABRB1
3 Cross references
102 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSSTOG00000003453
Gene Symbol: GABRB2
3 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSSTOG00000014493
Gene Symbol: GABRB3
3 Cross references
263 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSSTOG00000028473
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSSTOG00000001124
Gene Symbol: GABRE
4 Cross references
111 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSSTOG00000008607
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSSTOG00000011340
Gene Symbol: GABRG2
3 Cross references
204 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSSTOG00000000919
Gene Symbol: GABRG3
3 Cross references
255 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSSTOG00000010327
Gene Symbol: GABRQ
3 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSSTOG00000002478
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSSTOG00000004115
Gene Symbol: GABBR2
2 Cross references
241 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSSTOG00000028727
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).